Quantum Biopharma (QNTM) Current Deferred Revenue (2024 - 2025)
Quantum Biopharma (QNTM) posted Current Deferred Revenue of $1.0 million for Q1 2025, little changed sequentially from $1.0 million in Q4 2024.
Quantum Biopharma (QNTM) Current Deferred Revenue (2024 - 2025) Analysis & Trends
Quantum Biopharma has reported Current Deferred Revenue for 2 years, with the latest figure at $1.0 million in Q1 2025.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $1.0 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $1.0 million (changed N/A YoY) and the FY2024 annual result came in at $1.0 million, changed N/A from the prior year.
- Current Deferred Revenue held at $1.0 million in Q1 2025 per QNTM's latest filing, from $1.0 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $1.0 million in Q4 2024 and troughed at $1.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Quantum Biopharma | 15.44 Mn | 11.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 1.00 Mn |